TSXV:TRL.H - Post by User
Post by
alwaysmovingon May 13, 2017 1:53pm
339 Views
Post# 26240860
Results
ResultsI agree that the results are definitely not where I expected. But we need to keep into consideration the size of the Natesto market, in the same period Abbvie sold $136million worth of Androgel, we will break into this once the product becomes known. Androgel commercials are in constant repeat on US television, I'm sure Aytu will start to amp up sales. Estrace sales are down which was expected, I'm hoping management can come up with a solution to stop this trend. The upfront fee from Hyundai looks to be very small, about ~$200k... I'm hoping the additional licensing fee we receive once Natesto is approved in their market will be more in line with what Endo or even Aytu paid. An interesting comment I read in the Financials which I don't recall before was that Acerus is planning a third product using the "bio-adhesive Gel technology" which will treat anxiety. Of course I'm sure Tefina is their main priority before investing in another product development but I'm looking forward to hearing more about it. I'm hoping the call on Monday will bring more clarity to the Quarter.